QYResearch: General Observation of ADC drugs under clinical trial

Analyst: Carol (JIA LI)

Company: QYResearch

Key Drugs to Watch in 2016

1. Expecting IND for IMGN779.

2. Brentuximab vedotin for Lupus.

3. ABT -414 – just announced new phase II trial (intellace i).

4. Inotuzumab ozogamicin – Ino-vate-all – met first primary endpoint, waiting for overall survival analysis.

5. Expecting results from Echelon I and II – brentuximab vedotin (frontline treatment).

According to the study on new ADCs under clinical trial conducted by QYResearch. There are 59 ADCs in active clinical development worldwide. 

1. Enormous programs had been made over the last decade but much is still be achieved.

2. The last year alone has proved hugely exciting with many of the next generation of ADCs beginning clinical trials.

3. More companies than ever are committed to progressing the field and deliver meaningful drugs to patients.

4. Deeper understanding of what is driving responses and toxicity will be critical to improve the

therapeutic window of ADCs.

5. Dosing strategy can play an important role in improving tolerability.

All the innovation is clustered into phase 1 so the benefits of these new approaches will take time to show. Additionally, there is still a heavy reliance on just the technologies developed by ImmunoGen and Seattle Genetics – still over 70% of all trials use these payloads.

http://www.qyresearchglobal.com

This article was first released by QYResearch analyst, if reproduced, please indicate the source.

Media Contact: press@qyresearch.com

Analyst: lijia@qyresearch.com